DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

Williams bring more than 25 years of experience as a senior manager at major biotech firms, including Genzyme, an innovator and pioneer in pediatric rare diseases, as well as experience serving as founder/executive chairman of numerous entrepreneurial life sciences ventures. He brings experience and accomplishment in pediatric rare diseases, global development, business development, portfolio management and entrepreneurship.

Bush has more than 30 years of experience in biomedical R&D for major pharmaceutical companies, including Hoffman La-Roche, where he was responsible for the preclinical safety department at Nutley, N.J., as well as the non-clinical assessment of in-licensing candidates.

Goldstein brings more than 25 years of executive-level pharmaceutical and biotechnology expertise to DART with senior management roles at Sandoz, Novartis, SB (now GSK) and Maxygen.

Brown has co-founded several advisory and investment banking firms, including Carabiner, Seven Hills Group and Brown, McMillan & Co. Brown has spent more than 25 years working as an advisor to and investor in numerous companies across many segments of the healthcare industry.

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs